Organization | Changchun BCHT Biotechnology Co.

Changchun BCHT Biotechnology Co. Report issue

For profit Phase 1 Phase 3

Founded: Changchun China (2004)

Status: No NME R&D (2004)

Organization Overview

First Clinical Trial

2016

NCT02964065

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Changchun BCHT Biotechnology Co.

Active Ingredients

Drugs in Phase 3 Trials (2)

live attenuated influenza virus vaccine (Flumist) (3 trials)

live attenuated varicella vaccine (Varivax) (1 trial)

Drugs in Phase 1 Trials (3)

cbb 1 (1 trial)

inactivated rabies vaccine (Imovax) (1 trial)

rabies immune globulin (human) (HyperRAB) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Herpes Zoster (Phase 3)

Influenza, Human (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial APIs: 5